← Leaderboards
Kathryn Anne Defea
University Of California Riverside
$2,887,896
Attributed
$4,170,292
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $878.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,170,292 · 6
By mechanism
R44$1,671,055 · 1
R01$1,316,030 · 1
R41$893,738 · 3
R21$289,469 · 1
Top collaborators
- Scott Boitano4 shared
- Gregory O Dussor1 shared
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionReceptorResponseAffectPhysiologicalInflammatoryPathway InteractionsLeadBeta-ArrestinPharmaceutical PreparationsIn VivoPar-2 ReceptorInflammationIn VitroPlayCellsAgonistArrestinsBiologicalMediatingG-Protein-Coupled ReceptorsMuscle Relaxation PhaseExtrinsic AsthmaEpithelial
Grant awards (13)
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma$792,665
R44 · FY2025 · HL · contact PI
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma$878,390
R44 · FY2024 · HL · contact PI
Protease-activated-receptor-2 antagonists for treatment of migraine pain$310,351
R41 · FY2023 · NS · contact PI
Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics$300,000
R41 · FY2023 · HL · contact PI
Development of Small Molecule Antagonists of PAR-2 for treatment of asthma$283,387
R41 · FY2021 · HL · contact PI
Role of beta-arrestin-dependent chemotaxis in protease-activated-receptor-2-induc$146,254
R21 · FY2009 · HL · contact PI
Molecular Scaffolds Direct MAPK Signaling Specificity$102,818
R01 · FY2009 · GM · contact PI
Molecular Scaffolds Direct MAPK Signaling Specificity$236,380
R01 · FY2008 · GM · contact PI
Role of beta-arrestin-dependent chemotaxis in protease-activated-receptor-2-induc$143,215
R21 · FY2008 · HL · contact PI
Molecular Scaffolds Direct MAPK Signaling Specificity$236,380
R01 · FY2007 · GM · contact PI
Molecular Scaffolds Direct MAPK Signaling Specificity$243,440
R01 · FY2006 · GM · contact PI
Molecular Scaffolds Direct MAPK Signaling Specificity$248,506
R01 · FY2005 · GM
Molecular Scaffolds Direct MAPK Signaling Specificity$248,506
R01 · FY2004 · GM